99 results about "Inspiratory flow" patented technology

The present invention is directed to methods and devices for delivering an active agent formulation to the lung of a human patient. The active agent formulation may be in dry powder form, it may be nebulized, or it may be in admixture with a propellant. The active agent formulation is delivered to a patient at a low inspiratory flow rate for an initial period of time to increase bioavailability of the active agent.

A system for circuit compliance compensated volume assurance pressure control in a patient respiratory ventilation circuit, having a patient circuit volume estimator for estimating a patient circuit compliance, a patient circuit volume estimator to estimate a circuit volume VOL_{CKT<sub2>—</sub2>EST} based on the patient circuit compliance, a patient volume observer, for estimating a patient volume VOL_{TID<sub2>—</sub2>EST} based on a measure delivered net volume VOL_NET and the patient circuit compliance, a volume assurance controller for generating a circuit compliance volume compensation factor VOL_{TID<sub2>—</sub2>CTL} based on a preset assured volume VOL_{ASS<sub2>—</sub2>SET} and the estimated patient volume VOL_{TID<sub2>—</sub2>EST}, and a decelerating inspiratory flow controller, operative to generate a decelerating inspiratory peak flow based on a preset inspiratory time T_INSP and the volume compensation factor VOL_{TID<sub2>—</sub2>CTL}.

In accordance with one aspect of the present invention for controlled delivery of medicament to the respiratory system of a patient, a measured quantity of a medicament, i.e., a bolus 32 is introduced into the inspiratory flow stream of a patient, via a breathing tube 18, and inhaled by the action of the patient's breathing cycle of the course of a breathing cycle of the patient, numerous properties or characteristics of the medicament, i.e., the bolus, the inspiratory flow, like properties or characteristics of the expiratory flow, and/or other useful information are derived. The derived information is employed to control subsequent delivery of boli to the patient, including the delivery of each bolus as a function of the commencement or progression of the breathing cycle, as input for calculations or determinations which are useful in analyzing the effectiveness of delivery of the medicament to the patient, patient compliance, direction of flow through the breathing tube, and other uses.

The present invention is directed to methods and devices for delivering an active agent formulation to the lung of a human patient. The active agent formulation may be in dry powder form, it may be nebulized, or it may be in admixture with a propellant. The active agent formulation is delivered to a patient at an inspiratory flow rate of less than 17 liters per minute. The bioavailability of the active agent was found to increase at these flow rates when compared to inspiratory flow rates of 17 liters per minute or more.

The disclosure describes methods and inhalers that deagglomerate dry powder using inspiratory effort of a user of an inhaler. Inhaler fin and mesh configurations are described that facilitate deagglomeration. At least in steady state conditions, a dry powder and airflow pattern can be generated having turbulence with flow vortices, some of which may have a vortex having an axis of rotation that extends in an inspiratory flow direction while others may have a vortex that is substantially orthogonal to the inspiratory flow direction in an inspiratory airflow path, as an amount of dry powder travels through the inhaler to thereby deagglomerate the dry powder without trapping undue amounts of the dry powder during inhalation.

Embodiments provide aerosolization device for providing aerosolized medicament to user. The aerosolization device includes conduit, aerosol generator, fluid receiving chamber, restrictor within the conduit, and indicator mechanism. Conduit has an inner wall and a mouthpiece end for causing an inspiratory flow. Aerosol generator includes a vibratable mesh laterally offset from the inner wall. Fluid receiving chamber receives liquid medicament. At least a portion of chamber is tapered such that liquid medicament is directed onto vibratable mesh for aerosolization. Restrictor defines a plurality of apertures that provide increases in pressure differential that vary with inspiratory flow rate within conduit and provide relatively laminar flow downstream of restrictor. Indicator mechanism indicates a state of flow parameters relative to a predefined range. Aerosol generator is configured to aerosolize at least a portion of liquid medicament only when flow parameters of the inspiratory flow are within range.

This disclosure is directed to devices, systems, kits and methods for measuring peak expiratory or inspiratory flow-rate and dynamically predicting respiratory episodes. Additionally, systems for analyzing and processing the measurement in a communication networked environment are also provided. An aspect of the disclosure is directed to a respiratory device, In some configurations the respiratory device comprises a housing adaptable and configurable to communicate with an electronic device, a mouth piece having a proximal end and a distal end configurable to engage a mouth of a patient and transmit an air flow, one or more diaphragm sensors configured to detect a breath vibration from the air flow in the mouth piece, and a processor adaptable and configurable to analyze the breath vibration detected by the one or more diaphragm sensors.

In one aspect, embodiments of the present invention provide an aerosolization device for ensuring proper delivery of an aerosolized medication to a user's respiratory system. The aerosolization device may include a conduit, an aerosol generator, a restrictor disposed within the conduit, and an indicator mechanism. The conduit may include a mouthpiece end by which a user may cause inspiratory flow through the conduit. The aerosol generator may include a vibratable mesh. The restrictor may define a plurality of apertures disposed along an outer periphery of the restrictor configured to provide an increase in pressure differential that varies with an inspiratory flow rate within the conduit and to provide a relatively laminar flow downstream of the restrictor compared to upstream of the restrictor. The indicator mechanism may indicate to a user a state of a parameter of the inspiratory flow relative to a predefined desired range.

A human-machine synchronization method and device of an invasive ventilator operating in a noninvasive ventilation mode. The method includes steps of: measuring an airway pressure, an inspiratory flow, and an expiratory flow; calculating a gas leakage flow according to a pre-established gas leakage estimation model and by using the airway pressure, the inspiratory flow and the expiratory flow; and compensating a basic flow according to the gas leakage flow. In the above method, the gas leakage flow is estimated by means of the gas leakage estimation model, to compensate the gas leakage, thereby facilitating the noninvasive ventilation of the invasive ventilator and improving the human-machine synchronization.

A method and dispenser for treating a systemic disease in a patient in need of such treatment is disclosed. The method comprising maintaining the inspiratory flow rate and volume of the patient to a certain value and then administering a medicament aerosol formulation to the patient using a breath activated inhalation device.

The invention relates to a Zr-Co-Re thin film getter provided with a protection layer, and a preparation method thereof. The Zr-Co-Re thin film getter is composed of a getter layer and the protection layer; main components of the getter layer are Zr, Co, and one or more selected form rare earth elements La, Ce, Pr, and Nd; and main component of the protection layer is Ni. Pulsed laser deposition film plating is adopted, and deposition of the double-layer structured thin film getter containing the protection layer and the getter layer on texture monocrystalline silicon is carried out. The texture substrate is capable of increasing effective area of the getter thin film, and so that inspiratory flow rate and inspiratory capacity are increased. The surface of the getter layer is plated with a Ni protection layer; Ni is capable of realizing dissociation of hydrogen, and increasing absorption amount of hydrogen; and the Ni protection layer is capable of inhibiting absorption of oxygen and reducing activation temperature. Activation of the Zr-Co-Re thin film getter can be realized in roasting processes at a temperature of 180 to 350 DEG C; after roasting, the Zr-Co-Re thin film getter possesses excellent inspiration performance at room temperature, can be used for internal gas residue removing of high vacuum microelectronic devices.

A method for mobilizing an occlusion from a breathing tube is presented. The method includes automatically mobilizing the occlusion from the breathing tube by regulating an inspiratory flow, an expiratory flow, or a combination thereof, where the breathing tube is configured to operationally couple a patient to a ventilation system, and where the ventilation system is configured to provide artificial respiration to the patient.

A breathing circuit for a tracheostomized patient provides respiratory care and pulmonary function testing. The breathing circuit includes a flow control adapter that directs an inspiratory flow of air and an expiratory flow of air. The flow control adapter includes a subject port for coupling to a tracheostomy tube, an inspiratory port for coupling to an incentive spirometer, and an expiratory port. The flow control adapter further includes an adapter body and a one-way valve. The adapter body is configured to define an inspiratory fluid flow path between the inspiratory port and the subject port and to define an expiratory fluid flow path between the subject port and the expiratory port. The one-way valve substantially prevents air that flows generally along the inspiratory fluid flow path from flowing through the expiratory port during inspiration and allows air flowing generally along the expiratory fluid flow path to flow through the expiratory port during expiration.

In a method for continuous and non-invasive determination of the effective lung volume, the cardiac output, and/or the carbon dioxide content of venous blood of a subject during a sequence of respiratory cycles, the inspiratory and expiratory flow, and the carbon dioxide content of at least the expiration gas are measured. In each respiratory cycle, a first parameter related to the subject's fraction of alveolar carbon dioxide, a second parameter related to the carbon dioxide content of the subject's arterial blood, and a third parameter related to the subject's carbon dioxide elimination are determined based on the measured inspiratory flow, expiratory flow and carbon dioxide content. The effective lung volume, the cardiac output, and/or the carbon dioxide content of venous blood of the subject is determined based on the correlation of the first, second and third parameters.

The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.

The invention provides a medical intelligent ventilator comprising an expiration loop and an inspiration loop, which are connected with a breathing mask; the inspiration loop comprises an intelligent air-oxygen mixer, a bacterium filter, an inspiration valve, an inspiration flow meter, a pressure sensor A, a humidifying device and a heater, which are connected successively, the pressure sensor A being installed at the tail end of the inspiration loop. The expiration loop comprises a check valve, an expiration flow meter, a novel expiration valve and a water-removing bottle, which are connected successively. The breathing mask is internally provided with a carbon dioxide concentration sensor. The carbon dioxide concentration sensor, the pressure sensor A, the intelligent air-oxygen mixer, the inspiration flow meter and the expiration flow meter are connected with an ARM processor. The ARM processor is connected with an LED touch screen and an alarm. The medical intelligent ventilator can work according to the autonomous respiration of a patient, can maintain positive end-expiratory pressure of a patient, can discharge gas exhaled by a patient, is safer and can give alarm automatically.

The present invention provides an apparatus for determining a respiratory condition, wherein the apparatus includes:a signal acquirer which is configured to acquire a signal waveform corresponding to a respiratory flow of a subject; a differential calculator which is configured to acquire a differential waveform which is obtained by performing differentiation of the signal waveform; and a first determiner which is configured to determine that inspiratory flow limitation occurs in the subject, when the differential waveform satisfies a predetermined condition in a portion of the signal waveform, which corresponds to inspiration of the subject.

The invention relates to low flow rate cascade impactors for sampling aerosols, notably but not limited to pharmaceutical aerosols. The impactor stages serve as both orifice plate and collecting cup, simplifying collection and analysis. The impactor is designed to operate at flow rates approximating the inspiratory flow rates of young children and infants. Also presented is a method of and apparatus for applying a coating material to the collection surface of the stages after an impactor is assembled for use. The method entails generation of a polydisperse aerosol and sampling into the impactor. The coating substance improves the trapping of particles on the stages. The apparatus and method of application limit the amount of coating material applied and confines it to the regions of particle impact opposite the stage orifices.

A conduit connector assembly is provided for a respiratory therapy apparatus and configured to connect a patient interface to a gas delivery conduit. The assembly comprises: a conduit comprising a first flow port configured to be connected to the patient interface, and a second flow port configured to be connected to the gas delivery conduit, and a supplementary flow port; and a first valve port configured to be closed or opened by a valve flap. The conduit and the valve flap selectively provide an inspiratory flow path from the second flow port of the conduit to the first flow port of the conduit; and an expiratory flow path from the first flow port of the conduit to the supplementary flow port via the first valve port. A supplementary gas flow path is provided between the first and/or second flow ports and the supplementary flow port via a supplementary valve port.

An aspiration flow resistor 10 includes an inlet 12 and an outlet 14. A housing 16 is connected to the inlet 12 and outlet 14. A series of spaced walls 18 are disposed between the inlet 12 and the outlet 14. The walls 18 and the inlet 12 and the outlet 14 together with the housing 16 define a plurality of aspiration flow chambers 22. As aspirant flows from the inlet 12 to the outlet 14, a pressure decrease in the aspirant flow occurs at each wall 18 to provide resistance to aspirant flow.

A system and method for operating a ventilator to compensate for external gas flow reaching a patient from an external device, such as a nebulizer. A control unit of the ventilator monitors the gas flow rate from the ventilator and compares the gas flow rate from the ventilator to an expired gas flow rate from the patient. The difference between the inspired flow rate and the expired flow rate is due to the external device. The control unit modifies the operation of the ventilator to compensate for the external gas flow rate such that the flow of gas reaching the patient is maintained at a desired level.

The present disclosure pertains to a system and method for controlling insufflation pressure during inexsufflation of a subject. The system inexsufflates the subject such that tidal flow and/or tidal volume are monitored during insufflation, and insufflation pressure is adjusted to maintain the flow rate of the pressurized flow of breathable gas until a target tidal volume is reached for the insufflation. When the target tidal volume has substantially been reached, the system is causes gas to be evacuated from the airway of the subject. This may provide for more precise, customized therapy for the subject than is provided by conventional inexsufflation systems in which inspiratory flow may not be monitored and/or controlled. In one embodiment, the system comprises one or more of a pressure generator, a subject interface, one or more sensors, a processor, a user interface, electronic storage, and/or other components.